Takeda to Highlight Advancements in Rare Lysosomal Storage Disorders at Global Scientific Meeting
Takeda Pharmaceutical Company Limited today announced that it will feature 12 presentations, including 11 posters and one oral presentation, at the 15th annual WORLDSymposium™ 2019 in Orlando, Florida, February 4-8. Presentations and other company activities will focus on its research and development efforts in lysosomal storage disorders (LSDs) including Hunter syndrome (also known as Mucopolysaccharidosis type II or MPS II), type 1 Gaucher disease, Fabry disease and metachromatic leukodystrophy (also known as MLD).
The company will also sponsor a satellite symposium on the role of biomarkers in clinical management of lysosomal diseases, and a booth (Booth #105) in the WORLDSymposium exhibit hall.
The upcoming WORLDSymposium annual meeting focuses on the latest scientific and clinical research on LSDs, a collection of some 50 disorders caused by specific enzyme deficiencies and leading to significant disability and disease burden.
Read more: https://prn.to/2RDBX94
The company will also sponsor a satellite symposium on the role of biomarkers in clinical management of lysosomal diseases, and a booth (Booth #105) in the WORLDSymposium exhibit hall.
The upcoming WORLDSymposium annual meeting focuses on the latest scientific and clinical research on LSDs, a collection of some 50 disorders caused by specific enzyme deficiencies and leading to significant disability and disease burden.
Read more: https://prn.to/2RDBX94